1. Home
  2. CDE vs NBIX Comparison

CDE vs NBIX Comparison

Compare CDE & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coeur Mining Inc.

CDE

Coeur Mining Inc.

HOLD

Current Price

$17.68

Market Cap

13.5B

ML Signal

HOLD

Logo Neurocrine Biosciences Inc.

NBIX

Neurocrine Biosciences Inc.

HOLD

Current Price

$131.62

Market Cap

13.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDE
NBIX
Founded
1928
1992
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.5B
13.2B
IPO Year
1994
1996

Fundamental Metrics

Financial Performance
Metric
CDE
NBIX
Price
$17.68
$131.62
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
22
Target Price
$22.40
$180.91
AVG Volume (30 Days)
15.8M
1.1M
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
533.33
41.95
EPS
0.95
4.67
Revenue
$709,598,000.00
$161,626,000.00
Revenue This Year
$165.39
$24.73
Revenue Next Year
$12.10
$13.14
P/E Ratio
$18.81
$28.21
Revenue Growth
N/A
977.51
52 Week Low
$5.27
$108.47
52 Week High
$27.77
$160.18

Technical Indicators

Market Signals
Indicator
CDE
NBIX
Relative Strength Index (RSI) 41.38 53.32
Support Level $16.94 $124.62
Resistance Level $17.88 $135.30
Average True Range (ATR) 0.82 3.41
MACD -0.14 0.17
Stochastic Oscillator 14.01 70.73

Price Performance

Historical Comparison
CDE
NBIX

About CDE Coeur Mining Inc.

Coeur Mining Inc is a metals producer focused on mining precious minerals in the Americas. It is involved in the discovery and mining of gold and silver and generates the vast majority of revenue from the sale of these precious metals. The operating mines of the company are palmarejo, Rochester, Wharf, and Kensington. Its projects are located in the United States, Canada, and Mexico generating maximum revenue from United States.

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Share on Social Networks: